team cutanos

About cutanos

Cutanos GmbH is a biotech company founded in early 2021 focussing on the development of antigen-specific vaccines and new treatments for autoimmune disorders. Cutanos uses a modular and highly flexible drug delivery system called the Langerhans Cell Targeted Delivery System (LC-TDS). With this technology, the company aims to realize innovative immunotherapies in conjunction with minimally invasive administration. As a spin-off of the Max Planck Institute of Colloids and Interfaces, Cutanos will demonstrate the full range of its platform technology from their headquarter in Austrian capital of Vienna, financed by an equally motivated investment consortium (including KHAN-I, HTGF and IST cube).

Press releases

Cutanos Gründerteam
5. July 2021

Cutanos closes first financing round with investor consortium from Austria and Germany

Max Planck spin-off develops immunotherapies through innovative platform technology Vienna, July 5 2021 – Cutanos GmbH, a Viennese biotech start-up, announces the successful closing of its first financing round with KHAN Technology Transfer Fund I (KHAN-I), High-Tech Gründerfonds (HTGF), IST cube and another private investor. Cutanos was founded in early 2021 as a spin-off of the Max Planck Institute of Colloids and Interfaces. The core of the company is its Langerhans Cell Targ

Info & Contact

+43 676 576 01 86
Dr. Robert Wawrzinek, Managing Director


Cutanos GmbH
A-1090 Wien, Althanstrasse 14 (UZA II)

In portfolio

23. Apr 2021


Dr. Katharina Severin

Investment Manager